CY 216

Known as: CY-216, CY216 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1983-2005
02419832005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
This study compares some in vivo pharmacological properties of CY 216 and of its ACLM and BCLM components having a molecular… (More)
Is this relevant?
1994
1994
This study compares the pharmacokinetic and the antithrombotic properties of two pentasaccharides with high affinity to… (More)
Is this relevant?
1993
1993
Sixty-one consecutive patients were enrolled in a randomized, controlled trial of thromboprophylaxis with a low molecular weight… (More)
Is this relevant?
1993
1993
The inhibiting effect of standard heparin, CY216 and the ATIII-binding synthetic pentasaccharide on extrinsic and intrinsic… (More)
Is this relevant?
1992
1992
In 14 patients undergoing chronic hemodialysis, we investigated the safety and efficacy of the low molecular fragment (CY-216) in… (More)
Is this relevant?
1991
1991
Low molecular weight (LMW) heparin preparations have unknown distributions of ATIII-binding material, so mean molecular weights… (More)
Is this relevant?
1990
1990
Ninety consecutive outpatients with acute proximal and/or distal deep-vein thrombosis (DVT), as shown by phlebography, were… (More)
Is this relevant?
1990
1990
The effectiveness and safety of CY 216 as anticoagulant for extracorporeal circulation were evaluated in 403 haemodialysis of… (More)
Is this relevant?
1986
1986
Unfractionated heparin, pentosan polysulphate (SP54) and the low molecular weight heparins CY216 and CY222 were injected… (More)
Is this relevant?
1985
1985
The efficacy and safety of a low-molecular-weight (LMW) heparin fraction in preventing postoperative venous thrombo-embolism, was… (More)
Is this relevant?